Clarification Clarification

An article in BioWorld Today, Dec. 1, 1997, on IDEC Pharmaceuticals Corp. should have said the company, which received FDA approval for Rituxan (its monoclonal antibody to treat non-Hodgkin's lymphoma), also is developing a radioactive version of Rituxan for use in more advanced disease states with bulkier tumors. Phase II results for IDEC-Y2B8 — the ytrium-labeled monoclonal antibody — will be presented at the American Society of Hematology annual meeting Dec. 9.

No Comments